Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up 
Volkswagen Approves 50,000 More Job Cuts in Major Restructuring 
Lynas Rare Earths Shares Rise After Takeover Talks Revealed 
Audi, SAIC Launch China Innovation Hub for New AUDI Models 
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
South Korea, US Discuss Chip Investments Amid Tariff Plans 
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability 
Milei Threatens Falkland Oil Firms With Sanctions 
Tesla Cybercab Rides Launch in Austin as NHTSA Reviews Rollout 
Tesla Cybercab Launch Puts Robotaxi Ambitions in Focus 
Qantas Near-Miss Raises Sydney Air Traffic Controller Fatigue Concerns 
Fast Retailing Shares Drop as Uniqlo Japan August Sales Fall 
France Targets Shein, Temu With Fast-Fashion Fees 
OpenAI Launches GPT-6 Astra With Advanced AI Agent Capabilities 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
OpenAI Rejects Apple Trade Secret Theft Claims 
Add as a preferred source on Google
WALTHAM, Mass., March 05, 2018 -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release financial results and business updates for the fourth quarter and fiscal year ended December 31, 2017 on Monday, March 12, 2018. The Company will host a webcast and conference call that day at 8:30 a.m. Eastern Time to discuss these results and updates.
The live call may be accessed by dialing (877) 312-5845 for domestic callers or (765) 507-2618 for international callers and referring to conference ID number 1581007. A live webcast of the conference call will be available online under “Events and Presentations” in the Investors and Media section of the Company’s website at ir.minervaneurosciences.com. The archived webcast will be available on the Company’s website beginning approximately two hours after the event for 90 days.
About Minerva Neurosciences
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of product candidates to treat CNS diseases. Minerva’s proprietary compounds include: MIN-101, in Phase 3 clinical development for schizophrenia; seltorexant (MIN-202 or JNJ-42847922) in Phase 2b clinical development for insomnia and major depressive disorder (MDD); MIN-117, in clinical development for MDD; and MIN-301, in pre-clinical development for Parkinson’s disease. Minerva’s common stock is listed on the NASDAQ Global Market under the symbol “NERV.” For more information, please visit www.minervaneurosciences.com.
Contact:
William B. Boni
VP, Investor Relations/
Corp. Communications
Minerva Neurosciences, Inc.
(617) 600-7376
